Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors

细胞周期检查点激酶抑制剂的耐药机制

基本信息

  • 批准号:
    7629019
  • 负责人:
  • 金额:
    $ 30.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-10 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): DNA damaging anticancer agents induce arrest at various checkpoints throughout the cell cycle. This protective mechanism allows cells time to repair damage before progressing. UCN-01 (7-hydroxy-staurosporine) was identified as a potent inhibitor of the DNA damage-induced S and G2 arrest, thereby causing a marked enhancement in cell killing. UCN-01-mediated abrogation of normal cells is prevented by the p53 tumor suppressor protein. Thus, UCN-01 may selectively enhance chemotherapy in the tumor while sparing normal tissue. However, some p53-defective tumors are also resistant to UCN-01, while some p53-wildtype tumors are sensitive. This leads to the major question in this proposal: what are the determinants of response to checkpoint inhibitors? Aim 1 will focus on p53-defective tumor cell lines and investigate the role of Chk1 (inhibited by UCN-01) and other checkpoint kinases in arresting cell cycle progression. The response of various cell lines to different checkpoint inhibitors will be assessed. Three resistant tumor cell models will be analyzed for alternate kinases that explain their resistance to Chk1 and Chk2 inhibitors; candidate kinases include hSAD1, PLK3, MAPKAPK2 and JNK. To confirm the role of each kinase in checkpoint regulation, cell lines will be generated in which the kinase expression is prevented by siRNA. Aim 2 will address the question as to why some p53-wildtype tumors retain sensitivity to Chk1 inhibitors despite the fact that non-tumorigenic lines are resistant. Recent results demonstrate that p53 regulates the checkpoint through both gene activation (p21waf1) and repression (cyclin B) and that regulation of both of these proteins is defective in UCN-01-sensitive p53 wildtype tumors; p21 fails to be induced during S phase arrest, while cyclin B fails to be repressed during G2 arrest. The transcriptional and post-translational regulation of these two proteins will be studied and contributors to their differential regulation assessed. Experimental approaches will include dissection of the pathways through promoter analysis and chromatin immunoprecipitation assays. As novel checkpoint inhibitors enter clinical trial, the results of these studies will provide a basis upon which to stratify patients and thereby enhance the probability of developing a successful therapeutic regimen. For those tumors in which a response is not indicated, these experiments will likely identify alternate targets for drug discovery.
描述(由申请人提供):DNA损伤抗癌剂在整个细胞周期的各个检查点诱导阻滞。这种保护机制使细胞有时间修复损伤。UCN-01(7-羟基星孢素)被鉴定为DNA损伤诱导的S和G2阻滞的有效抑制剂,从而引起细胞杀伤的显着增强。p53肿瘤抑制蛋白可阻止ucn -01介导的正常细胞凋亡。因此,UCN-01可能选择性地增强肿瘤的化疗,同时保留正常组织。然而,一些p53缺陷型肿瘤对UCN-01也有耐药性,而一些p53野生型肿瘤对UCN-01敏感。这就引出了本提案中的主要问题:什么是对检查点抑制剂反应的决定因素?Aim 1将专注于p53缺陷的肿瘤细胞系,并研究Chk1(被UCN-01抑制)和其他检查点激酶在阻止细胞周期进展中的作用。各种细胞系对不同检查点抑制剂的反应将被评估。将分析三种耐药肿瘤细胞模型的替代激酶,解释它们对Chk1和Chk2抑制剂的耐药性;候选激酶包括hSAD1、PLK3、MAPKAPK2和JNK。为了确认每个激酶在检查点调节中的作用,将产生被siRNA阻止激酶表达的细胞系。Aim 2将解决为什么一些p53野生型肿瘤保留对Chk1抑制剂的敏感性,尽管事实上非致瘤性系具有耐药性。最近的研究结果表明,p53通过基因激活(p21waf1)和抑制(cyclin B)来调节检查点,并且在ucn -01敏感的p53野生型肿瘤中,这两种蛋白的调节都是有缺陷的;p21在S期阻滞期间不能被诱导,而cyclin B在G2期阻滞期间不能被抑制。这两种蛋白的转录和翻译后调控将被研究,并对其差异调控的贡献者进行评估。实验方法将包括通过启动子分析和染色质免疫沉淀分析来解剖通路。随着新的检查点抑制剂进入临床试验,这些研究的结果将为患者分层提供基础,从而提高开发成功治疗方案的可能性。对于那些没有反应的肿瘤,这些实验可能会确定药物发现的替代靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALAN R EASTMAN其他文献

ALAN R EASTMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALAN R EASTMAN', 18)}}的其他基金

Cancer Biology and Molecular Therapeutics
癌症生物学和分子治疗
  • 批准号:
    7921845
  • 财政年份:
    2009
  • 资助金额:
    $ 30.38万
  • 项目类别:
MOLECULAR THERAPEUTICS RESEARCH PROGRAM
分子治疗研究计划
  • 批准号:
    7944597
  • 财政年份:
    2009
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    7483072
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    8633002
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    9036264
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    7257577
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    7864084
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    8499599
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    9243917
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    8074512
  • 财政年份:
    2007
  • 资助金额:
    $ 30.38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了